(R)-methyl 3-(7-methoxy-4-oxochroman-2-yl)benzoate | 1438761-56-8

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 黄酮类化合物
• 英文名称: (R)-methyl 3-(7-methoxy-4-oxochroman-2-yl)benzoate
• 英文别名: methyl 3-[(2R)-7-methoxy-4-oxo-3,4-dihydro-2H-1-benzopyran-2-yl]benzoate；methyl 3-[(2R)-7-methoxy-4-oxo-2,3-dihydrochromen-2-yl]benzoate
• CAS: 1438761-56-8
• 化学式: C₁₈H₁₆O₅
• 分子量: 312.322
• InChiKey: HUCYSBNHPXZEDZ-MRXNPFEDSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  23
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  61.8
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (R)-methyl 3-(7-methoxy-4-oxochroman-2-yl)benzoate 在 吡啶 、 platinum(IV) oxide 、 potassium trimethylsilonate 、 氢气 、 溶剂黄146 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 20.0~60.0 ℃ 、101.33 kPa 条件下， 反应 29.0h， 生成 3-[(2R,4R)-7-methoxy-4-{[1-methyl-6-(trifluoromethoxy)-2,3-dihydro-1H-indene-1-carbonyl]amino}-3,4-dihydro-2H-1-benzopyran-2-yl]benzoic acid
  参考文献：
  名称：

  MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN

  摘要：

  本发明提供了以下式（I）的化合物，其中R1、m、Z、G1、R2和R3具有规范中定义的任何值，以及其药学上可接受的盐，这些化合物可用作治疗由CFTR介导和调节的疾病和症状的药物，包括囊性纤维化、Sjögren综合征、胰腺功能不全、慢性阻塞性肺病和慢性阻塞性气道疾病的药物。还提供了由一个或多个式（I）化合物组成的药物组合物。

  公开号：

  US20170305891A1
• 作为产物：
  描述：

  3-(dimethylamino)-1-(4-ethoxy-2-hydroxyphenyl)prop-2-en-1-one 在 盐酸 、 ammonium hexafluorophosphate 、 palladium(II) trifluoroacetate 、 (S)-4-叔丁基-2-(2-氮苯基)恶唑啉 作用下， 以 二氯甲烷 、 水 、 1,2-二氯乙烷 为溶剂， 反应 1.08h， 生成 (R)-methyl 3-(7-methoxy-4-oxochroman-2-yl)benzoate
  参考文献：
  名称：

  [EN] SUBSTITUTED CHROMANES AND METHOD OF USE
  [FR] CHROMANES SUBSTITUÉS ET MÉTHODE D'UTILISATION

  摘要：

  该发明提供了一种公式（I）化合物，其中R1、X、Y、R4、R5、R6、R7、R8、R9、R10、R11、R12、R13、R14、m和R"具有规范中定义的任何值，以及其药学上可接受的盐，这些化合物在治疗由CFTR介导和调节的疾病和症状中是有用的，包括囊性纤维化、Sjögren综合征、胰腺功能不全、慢性阻塞性肺病和慢性阻塞性气道疾病。还提供了由一个或多个公式（I）化合物组成的药物组合物。

  公开号：

  WO2016069757A1

文献信息

• Palladium-Catalyzed Asymmetric Conjugate Addition of Arylboronic Acids to Heterocyclic Acceptors
  作者：Jeffrey C. Holder、Alexander N. Marziale、Michele Gatti、Bin Mao、Brian M. Stoltz

  DOI：10.1002/chem.201203643

  日期：2013.1.2

  Flava Flavanone: Asymmetric conjugate additions to chromones and 4‐quinolones are reported utilizing a single catalyst system formed in situ from Pd(OCOCF3)2 and (S)‐tBuPyOX. Notably, these reactions are performed in wet solvent under ambient atmosphere, and employ readily available arylboronic acids as the nucleophile, thus providing ready access to these asymmetric heterocycles (see scheme).

  Flava 黄烷酮：据报道，使用由 Pd(OCOCF 3 ) 2和 ( S ) -t BuPyOX原位形成的单一催化剂体系，不对称共轭加成到色酮和 4-喹诺酮。值得注意的是，这些反应是在环境气氛下在湿溶剂中进行的，并使用容易获得的芳基硼酸作为亲核试剂，从而提供了对这些不对称杂环的快速访问（参见方案）。
• SUBSTITUTED TRICYCLICS AND METHOD OF USE
  申请人：AbbVie S.à.r.l.

  公开号：US20170015675A1

  公开（公告）日：2017-01-19

  The present invention provides for compounds of formula (I) wherein X, Y, and R 1 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).

  本发明提供了一种具有以下结构的化合物（I），其中X、Y和R1具有规范中定义的任何值，以及其药学上可接受的盐，这些化合物在治疗由CFTR介导和调节的疾病和症状中是有用的，包括囊性纤维化、Sjögren综合征、胰腺功能不全、慢性阻塞性肺病和慢性阻塞性气道疾病。还提供了由一个或多个具有结构（I）的化合物组成的药物组合物。
• SUBSTITUTED CHROMANES AND METHOD OF USE
  申请人：AbbVie Inc.

  公开号：US20160120841A1

  公开（公告）日：2016-05-05

  The invention provides for compounds of formula (I) wherein R 1 , X, Y, R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , m, and R″ have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).

  本发明提供了以下式子(I)的化合物，其中R1、X、Y、R4、R5、R6、R7、R8、R9、R10、R11、R12、R13、R14、m和R″的任何一个取值均符合规范要求，并且其药学上可接受的盐，在治疗由CFTR介导和调节的疾病和病状中具有作用，包括囊性纤维化、Sjögren综合征、胰腺功能不全、慢性阻塞性肺病和慢性阻塞性气道疾病。还提供了由一个或多个式(I)化合物组成的制药组合物。
• Discovery of 4-[(2<i>R</i>,4<i>R</i>)-4-({[1-(2,2-Difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl}amino)-7-(difluoromethoxy)-3,4-dihydro-2<i>H</i>-chromen-2-yl]benzoic Acid (ABBV/GLPG-2222), a Potent Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Corrector for the Treatment of Cystic Fibrosis
  作者：Xueqing Wang、Bo Liu、Xenia Searle、Clinton Yeung、Andrew Bogdan、Stephen Greszler、Ashvani Singh、Yihong Fan、Andrew M Swensen、Timothy Vortherms、Corina Balut、Ying Jia、Kelly Desino、Wenqing Gao、Hong Yong、Chris Tse、Philip Kym

  DOI：10.1021/acs.jmedchem.7b01339

  日期：2018.2.22

  Cystic fibrosis (CF) is a multiorgan disease of the lungs, sinuses, pancreas, and gastrointestinal tract that is caused by a dysfunction or deficiency of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, an epithelial anion channel that regulates salt and water balance in the tissues in which it is expressed. To effectively treat the most prevalent patient population (F508del mutation), two biomolecular modulators are required: correctors to increase CFTR levels at the cell surface, and potentiators to allow the effective opening of the CFTR channel. Despite approved potentiator and potentiator/corrector combination therapies, there remains a high need to develop more potent and efficacious correctors. Herein, we disclose the discovery of a highly potent series of CFTR correctors and the structureactivity relationship (SAR) studies that guided the discovery of ABBV/GLPG-2222 (22), which is currently in clinical trials in patients harboring the F508del CFTR mutation on at least one allele.
• Substituted Chromanes and Method of Use
  申请人：AbbVie S.à.r.l.

  公开号：US20190127356A1

  公开（公告）日：2019-05-02

  The invention provides for compounds of formula (I) wherein R 1 , X, Y, R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , m, and R″ have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).